Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710020 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01710020 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT01710020, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a second period (Period 2) will be conducted. In Period 2, a single dose of drug will be administered approximately 4 hours prior to hemodialysis.
Interventions
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2003-02 |
| Est. Completion | 2003-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710020
The ClinicalTrials.gov registry entry for NCT01710020 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-690,550 is the first listed.
NCT01710020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01710020 about?
NCT01710020 is a clinical study titled "Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease". There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a second period (Period 2) ...
What is the current status of trial NCT01710020?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2003-02. Estimated completion is 2003-06.
What interventions are being tested in trial NCT01710020?
The interventions under investigation include: CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT01710020?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.